NewsRoom Articles - Page 35 of 234

ThursdayApr 17, 2025 10:00 am

The Global Market for Brain Tumor Treatments Will Reach $7.15 Billion by 2035

The global market for brain tumor treatments is experiencing significant transformation powered by advances in immunotherapy, personalized medicine and targeted therapy. The market is projected to grow at a 7.2% CAGR to reach $7.15 billion by 2035, according to a report published by Future Market Insights. The report indicates that this market is entering a new phase of growth propelled by the increasing prevalence of malignant brain tumors, such as glioblastoma, in addition to a remarkable increase in investments in the neuro-oncology field. Many cutting-edge interventions are being integrated in the way patients are treated. These include tumor-treating fields and…

TuesdayApr 15, 2025 10:00 am

New Blood Test Shows Potential in Revolutionizing Early Parkinson’s Detection

A team of researchers has developed a “cost-effective” and simple blood test with the potential to detect Parkinson’s disease years before the disease’s symptoms start manifesting. The study’s findings appeared in the Nature Aging journal. Approximately 153,000 individuals live with Parkinson’s disease in the United Kingdom, and the team that conducted this recent research is optimistic that their innovation could revolutionize how early the disease can be detected. This early diagnosis would then allow treatment teams to initiate interventions that improve the clinical outcomes for patients. The new test developed focuses on analyzing fragments of transfer RNA (tRFs), which are…

TuesdayApr 15, 2025 9:45 am

Nutriband Inc. (NASDAQ: NTRB) Is ‘One to Watch’

Nutriband’s AVERSA technology has the potential to improve the safety profile of transdermal drugs susceptible to abuse, like fentanyl, while keeping these drugs accessible to patients. AVERSA technology can be incorporated into any transdermal patch. The company has a broad and expanding intellectual property portfolio protecting AVERSA, with patents granted in the U.S., Europe, Japan, Korea, Russia, Canada, Mexico, Australia, and China. Nutriband closed an $8.4 million financing round in April 2024 to support commercial development of AVERSA Fentanyl, its abuse-deterrent fentanyl transdermal patch. In February 2025, the company formalized a long-term exclusive partnership with Kindeva Drug Delivery to support…

MondayApr 14, 2025 9:00 am

Nutriband Inc. (NASDAQ: NTRB) Leading the Way in Transformative Partnerships Formed in Growing Pharma Sector

Strategic partnerships embrace opportunities to foster innovation, streamline processes and ultimately improve the lives of patients Nutriband recently announced two significant partnerships poised to expand its manufacturing capabilities and market reach These partnerships, along with the company’s already existing alliances, align with Nutriband's core mission of developing transdermal pharmaceutical products Strategic alliances are vital to success in the pharmaceutical sector, where innovation, regulatory navigation and market access are complex and resource-intensive. Collaborations between biotech firms, research institutions and major pharmaceutical companies accelerate drug development, reduce costs and enhance the likelihood of regulatory approval. Nutriband (NASDAQ: NTRB), a company focused on…

FridayApr 11, 2025 10:45 am

Adageis Helps Medical Providers Track and Build Revenue Through Efficient Application of Value-Based Care

Adageis provides clinics and medical groups with AI-powered tools to track financial outcomes tied to quality care, in profitable shift from fee-for-service to value-based models. Its system helps decipher complex insurance contracts to maximize reimbursements. The software helps decipher complex insurance contracts to maximize reimbursements, integrating smoothly with major electronic health record systems to identify high-risk patients and care gaps. Adageis is continuously working with investors to expand its offerings for a growing list of small and independent practices. Adageis, a forward-thinking healthcare technology company focused on value-based care solutions, is helping clinics and medical groups measure how their delivery…

FridayApr 11, 2025 10:00 am

Blocking an Enzyme in Melanoma Patients Could Overcome Resistance to Immunotherapy

Approximately 65% of patients diagnosed with melanoma are unresponsive to immunotherapy. New research suggests that blocking the HPGDS enzyme can be a viable way to improve patients’ response to immunotherapy since the activity of this enzyme contributes to immunotherapy resistance. This approach can also increase immunotherapy response in other types of cancer with similar attributes to those of melanoma. Over the last 10 years, significant advances have been made in leveraging immunotherapy to treat melanoma and other cancers. However, more than half (65%) of melanoma patients don’t respond to immunotherapy. TAMs (tumor-associated macrophages) play a major role in this immunotherapy…

ThursdayApr 10, 2025 10:00 am

Health Insurance Shares Climb After Medicare Reimbursements are Boosted

Shares of health insurance firms in the U.S. jumped after the federal government announced a reimbursement rate increase which was higher than what had been expected by the industry. The rate increase applies to Medicare Advantage plans and will take effect next year. This increase was welcome news to the industry that had seen their margins squeezed by rising costs of medical care. Humana, an insurer specializing in Medicare, saw its shares soar by 16% while other firms, such as Centene, UnitedHealth Group and CVS saw upticks ranging from 5% to 10%. After the Covid-19 pandemic, there was a surge…

TuesdayApr 08, 2025 10:00 am

Study Shows the Gut is Key in Protecting the Brain After Stroke

Many patients who have had a stroke often suffer secondary brain damage as a result of the inflammation that is triggered during the stroke. Scientists have been working to find ways to forestall this secondary brain damage and a recent preclinical study conducted by a team at UTHealth Houston could provide a viable way to address neuroinflammation after stroke episodes. For their study, the team focused on molecules whose role is to bind to particular receptors. These molecules are called ligands, mainly produced in the gut. Ligands are vital in facilitating cell function and signaling between different parts of the…

TuesdayApr 08, 2025 9:00 am

Soligenix Inc. (NASDAQ: SNGX) Spotlighted in Recent Zacks Small-Cap Research Report, Earns a $35 Valuation

Recent Zacks report supports a $35 per share valuation and provides an in-depth evaluation of Soligenix. The Zacks report underscores Soligenix's strategic focus on rare diseases and areas lacking effective treatments. Financially, Soligenix has demonstrated resilience amid the challenges inherent in biopharmaceutical development. Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company specializing in developing and commercializing products to treat rare diseases, has recently been the focus of a comprehensive analysis by Zacks Small-Cap Research (https://ibn.fm/OpnDo). The report supports a $35 per share valuation and provides an in-depth evaluation of Soligenix's diverse product pipeline, financial health and strategic positioning within the biopharmaceutical industry.…

MondayApr 07, 2025 10:00 am

Study Uncovers Drivers of Brain Tumor Growth, Could Open New Treatment Approaches

A new study has uncovered key drivers of brain cancer growth that could make it possible to predict or even slow down the rate at which these tumors regrow. This could open a new chapter in personalized cancer treatment. The research team, led by Professor Parag Katira of San Diego State University, together with Moffit Cancer Center’s Ana Gomes and Noemi Andor, discovered how brain tumor cells grow and transform in response to the environment in which they find themselves. These findings could enable doctors to predict the cancer’s response to any treatments to be administered. The team focused their…